Hepatitis Monthly

Published by: Kowsar

Transcatheter Arterial Chemoembolization Therapy for Patients With Unresectable Hepatocellular Carcinoma

Kavous Firouznia 1 , Hossein Ghanaati 1 , * , Seyed Moayed Alavian 2 , Payam Azadeh 3 , Mohsen Nasiri Toosi 4 , Arya Haj Mirzaian 1 , Safa Najafi 5 , Madjid Shakiba 1 and Amir Hossein Jalali 1
Authors Information
1 Advanced Diagnostic and Interventional Radiology Research Center (ADIR), Tehran University of Medical Sciences, Tehran, IR Iran
2 Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
3 Department of Radiation Oncology, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
4 Internal Medicine Department, Imam-Khomeini Hospital, Tehran University of Medical Sciences (TUMS), Tehran, IR Iran
5 Tehran University of Medical Sciences, Tehran, IR Iran
Article information
  • Hepatitis Monthly: December 2014, 14 (12); e25792
  • Published Online: December 28, 2014
  • Article Type: Research Article
  • Received: December 3, 2014
  • Accepted: December 17, 2014
  • DOI: 10.5812/hepatmon.25792

To Cite: Firouznia K, Ghanaati H, Alavian S M, Azadeh P, Nasiri Toosi M, et al. Transcatheter Arterial Chemoembolization Therapy for Patients With Unresectable Hepatocellular Carcinoma, Hepat Mon. 2014 ;14(12):e25792. doi: 10.5812/hepatmon.25792.

Copyright: Copyright © 2014, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Cook GC. Hepatocellular carcinoma: one of the world's most common malignancies. Q J Med. 1985; 57(223): 705-8[PubMed]
  • 2. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999; 340(10): 745-50[DOI][PubMed]
  • 3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55(2): 74-108[PubMed]
  • 4. Ataei B, Tayeri K, Kassaian N, Farajzadegan Z, Babak A. Hepatitis B and C among patients infected with human immunodeficiency virus in Isfahan, Iran: seroprevalence and associated factors. Hepat Mon. 2010; 10(3): 188-92[PubMed]
  • 5. Alavian SM, Fallahian F, Lankarani KB. The changing epidemiology of viral hepatitis B in Iran. J Gastrointestin Liver Dis. 2007; 16(4): 403-6[PubMed]
  • 6. Ali F, Iman F, Babak E, Parivash S, Parisa F, Yaser G, et al. screening for hepatocellular carcinoma in chronic carriers of hepatitis B and C in markazi province, iran. Hepat Mon. 2007; (3): 149-52
  • 7. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985; 56(4): 918-28[PubMed]
  • 8. Hajiani E, Masjedizadeh R, Hashemi J, Azmi M, Rajabi T. Risk factors for hepatocellular carcinoma in Southern Iran. Saudi Med J. 2005; 26(6): 974-7[PubMed]
  • 9. Lehnert T, Herfarth C. Chemoembolization for hepatocellular carcinoma. What, when, and for whom? Ann Surg. 1996; 224(1): 1-3[PubMed]
  • 10. Maleux G, van Malenstein H, Vandecaveye V, Heye S, Vaninbroukx J, Nevens F, et al. Transcatheter chemoembolization of unresectable hepatocellular carcinoma: current knowledge and future directions. Dig Dis. 2009; 27(2): 157-63[DOI][PubMed]
  • 11. Chung YH, Song IH, Song BC, Lee GC, Koh MS, Yoon HK, et al. Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer. 2000; 88(9): 1986-91[PubMed]
  • 12. Ando E, Yamashita F, Tanaka M, Tanikawa K. A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein. Cancer. 1997; 79(10): 1890-6[PubMed]
  • 13. Jaeger HJ, Mehring UM, Castaneda F, Hasse F, Blumhardt G, Loehlein D, et al. Sequential transarterial chemoembolization for unresectable advanced hepatocellular carcinoma. Cardiovasc Intervent Radiol. 1996; 19(6): 388-96[PubMed]
  • 14. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. N Engl J Med. 1995; 332(19): 1256-61[DOI][PubMed]
  • 15. Cakmakci E, Caliskan KC, Tabakci ON, Tahtabasi M, Karpat Z. Percutaneous liver biopsies guided with ultrasonography: a case series. Iran J Radiol. 2013; 10(3): 182-4[DOI][PubMed]
  • 16. Ghanaati H, Alavian SM, Jafarian A, Ebrahimi Daryani N, Nassiri-Toosi M, Jalali AH, et al. Imaging and Imaging-Guided Interventions in the Diagnosis and Management of Hepatocellular Carcinoma (HCC)-Review of Evidence. Iran J Radiol. 2012; 9(4): 167-77[DOI][PubMed]
  • 17. Ghanaati H, Firouznia K, Jalali AH, Shakiba M. How to Start Interventional Radiology. Iran Red Crescent Med J. 2013; 15(12)[DOI]
  • 18. Valls C, Pamies JJ, Sancho C, Benasco C, Figueras J, Dominguez J, et al. Computed tomography after Lipiodol chemoembolization in hepatocellular carcinoma. Eur Radiol. 1994; 4(3): 238-42[DOI]
  • 19. Caglayan B, Salepci B, Dogusoy I, Fidan A, Sener Comert S, Kiral N, et al. The role of convex probe endobronchial ultrasound guided transbronchial needle aspiration in the diagnosis of malignant mediastinal and hilar lymph nodes. Iran J Radiol. 2012; 9(4): 183-9[DOI][PubMed]
  • 20. Ghanaati H, Firouznia K, Jalali AH, Shakiba M. Advances of interventional radiology in treatment of hepatobiliary diseases in Iran. Hepat Mon. 2011; 11(7): 507-10[PubMed]
  • 21. Rajesh R, Dalip DS, Anupam J, Jaisiram A. Effectiveness of puncture-aspiration-injection-reaspiration in the treatment of hepatic hydatid cysts. Iran J Radiol. 2013; 10(2): 68-73[DOI][PubMed]
  • 22. Ngan H, Lai CL, Fan ST, Lai EC, Yuen WK, Tso WK. Transcatheter arterial chemoembolization in inoperable hepatocellular carcinoma: four-year follow-up. J Vasc Interv Radiol. 1996; 7(3): 419-25[PubMed]
  • 23. Gadaleta CD, Ranieri G. Trans-arterial chemoembolization as a therapy for liver tumours: New clinical developments and suggestions for combination with angiogenesis inhibitors. Crit Rev Oncol Hematol. 2011; 80(1): 40-53[DOI][PubMed]
  • 24. Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol. 2007; 30(1): 6-25[DOI][PubMed]
  • 25. Vogl TJ, Naguib NN, Nour-Eldin NE, Rao P, Emami AH, Zangos S, et al. Review on transarterial chemoembolization in hepatocellular carcinoma: palliative, combined, neoadjuvant, bridging, and symptomatic indications. Eur J Radiol. 2009; 72(3): 505-16[DOI][PubMed]
  • 26. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology. 2004; 127(5 Suppl 1)-88[PubMed]
  • 27. Solomon B, Soulen MC, Baum RA, Haskal ZJ, Shlansky-Goldberg RD, Cope C. Chemoembolization of hepatocellular carcinoma with cisplatin, doxorubicin, mitomycin-C, ethiodol, and polyvinyl alcohol: prospective evaluation of response and survival in a U.S. population. J Vasc Interv Radiol. 1999; 10(6): 793-8[PubMed]
  • 28. Georgiades CS, Hong K, D'Angelo M, Geschwind JF. Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol. 2005; 16(12): 1653-9[DOI][PubMed]
  • 29. Liapi E, Geschwind JF. Intra-arterial therapies for hepatocellular carcinoma: where do we stand? Ann Surg Oncol. 2010; 17(5): 1234-46[DOI][PubMed]
  • 30. Goin JE, Roberts CA, Dancey JE, Sickles CJ, Leung DA, Soulen MC. Comparison of post-embolization syndrome in the treatment of patients with unresectable hepatocellular carcinoma: trans-catheter arterial chemo-embolization versus yttrium-90 glass microspheres. World J Nucl Med. 2004; 3(1): 49-56
  • 31. Chan AO, Yuen MF, Hui CK, Tso WK, Lai CL. A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer. 2002; 94(6): 1747-52[PubMed]
  • 32. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology. 2003; 37(2): 429-42[DOI][PubMed]
  • 33. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002; 359(9319): 1734-9[DOI][PubMed]
  • 34. Kawai S, Okamura J, Ogawa M, Ohashi Y, Tani M, Inoue J, et al. Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma--a comparison of lipiodol-transcatheter arterial embolization with and without adriamycin (first cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. Cancer Chemother Pharmacol. 1992; 31 Suppl-6[PubMed]
  • 35. O'Suilleabhain CB, Poon RT, Yong JL, Ooi GC, Tso WK, Fan ST. Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma. Br J Surg. 2003; 90(3): 325-31[DOI][PubMed]
  • 36. Yamada R, Kishi K, Sato M, Sonomura T, Nishida N, Tanaka K, et al. Transcatheter arterial chemoembolization (TACE) in the treatment of unresectable liver cancer. World J Surg. 1995; 19(6): 795-800[PubMed]
  • 37. Reidy DL, Schwartz JD. Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials-I: hepatic arterial embolization and embolization-based therapies in unresectable hepatocellular carcinoma. Anticancer Drugs. 2004; 15(5): 427-37[PubMed]
  • 38. Ikeda M, Okada S, Yamamoto S, Sato T, Ueno H, Okusaka T, et al. Prognostic factors in patients with hepatocellular carcinoma treated by transcatheter arterial embolization. Jpn J Clin Oncol. 2002; 32(11): 455-60[PubMed]
  • 39. Mondazzi L, Bottelli R, Brambilla G, Rampoldi A, Rezakovic I, Zavaglia C, et al. Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma: a multivariate analysis of prognostic factors. Hepatology. 1994; 19(5): 1115-23[PubMed]
  • 40. Llado L, Virgili J, Figueras J, Valls C, Dominguez J, Rafecas A, et al. A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. Cancer. 2000; 88(1): 50-7[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader